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Copyright © 2010 JCBN Summary Non-steroidal anti-inflammatory drug (NSAID)-related small intestinal complica-
tions exist, since developed new diagnostic modalities, such as balloon and capsule endoscopies.
Some experiments have shown rebamipide to protect from NSAID-induced small intestinal
complications. The purpose of this study is to investigate whether the effective concentrations
of rebamipide (COR) are present in the small intestine after taking an ordinary clinical dose
and double dose of this drug. Twelve healthy male subjects were enrolled. After taking 100 or
200 mg of rebamipide, balloon enteroscopy was performed at 1 and 3 h, and biopsy samples
were obtained from the jejunum and the stomach. Venous blood samples were taken simulta-
neously. Samples were analyzed by high-performance liquid chromatography. The mean COR
in the jejunum was higher than 100 µM at 1 h and higher than 10 µM at 3h in both the 100
and 200 mg groups. Mean COR in the stomach was less than 100 µM at 1 h in the 100 mg
group; however it was higher than 100 µM in the 200 mg group. In conclusion, the COR level
in the jejunum was sufficient to protect for NSAID-induced gastrointestinal complications.
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Introduction
The use of non-steroidal anti-inflammatory drugs
(NSAIDs) including aspirin is common in the treatment of
fever and pain. Furthermore, low-dose aspirin is generally
used as a prophylaxis in cardiovascular and cerebrovascular
events. However, these agents are well-known to cause the
adverse event of mucosal damage in the gastrointestinal (GI)
tract [1–3]. In recent years, NSAID-related complications
have been reported in the stomach and small intestine.
Bjarnason et al. [4] reported that NSAIDs caused inflam-
mation of the small intestine in 70% of patients receiving
long-term administration of these drugs. This inflammation
can cause bleeding, protein loss, perforation, and strictures
in the small intestine [5–7].
The pathogenesis of small-intestinal damage due to
NSAIDs has been partially elucidated. Increased intestinal
permeability is thought to be the essential mechanism
underlying the translation of biochemical/cellular events of
NSAIDs to a tissue reaction; furthermore, translocated
bacteria and their degradation products lead to neutrophil
infiltration in the small intestine [8]. On the other hand,
biochemical actions of NSAIDs, such as cyclooxygenase
(COX)-1 inhibition, which cause prostaglandin deficiency
[9], damage the small intestine. NSAID-induced gastric
mucosal injury can be prevented by the use of proton pump
inhibitor [10], misoprostol [11], and rebamipide [12–14],
however a drug for the prevention of intestinal complications
related to these agents has not been developed until now.Local Tissue Concentration of Rebamipide
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Rebamipide {2-(4-chlorobenzylamino)-3-[2(1H)-quino-
linon-4-yl] propionic acid, Otsuka Pharmaceutical Co.,
Tokyo, Japan} is a anti-gastric ulcer and gastritis agent.
This agent is known to have preventive effects against
various acute experimental gastric mucosal lesions and to
accelerate the healing of gastric ulcer. Increased mucous
secretion [15], enhanced generation of endogenous pro-
staglandins [16], suppression of neutrophil function [17],
inhibition of inflammatory cytokines [18], and scavenging
of oxygen free radicals [19] have been known to be impor-
tant effects of rebamipide in the stomach. Likewise, in the
mucosa of the small intestine, rebamipide’s protective
effects have been reported. Banan et al. [20] demonstrated
that rebamipide prevented oxidation of actin and lead to
the protection of actin cytoskeleton using in vitro human
intestinal cell monolayers. Accordingly, they suggested
that this agent prevented intestinal hyperpermeability and
stabilized human intestinal barrier function. Mizoguchi et al.
[21] reported protective effects of rebamipide against
indomethacin-induced intestinal damage in rats, and sug-
gested that the mechanism underlying its preventive action
was due to the scavenging of oxygen free radicals. These
pharmacological actions have been confirmed by in vitro
experimental studies to require concentration of rebamipide
(COR) of more than 1 µM to 100 µM [15–21].
Drug delivery in the human small intestine has not been
examined until now because of the difficulty of obtaining
small intestinal specimen. Using balloon enteroscopy, it is
possible to successfully obtain biopsy samples of the
jejunum after taking rebamipide. This is the first report on
the delivery of this drug to the human small intestine.
The purpose of this study was to investigate whether an
effective COR was achieved in the small intestine after
taking an ordinary clinical dose and double dose of this drug
by using healthy subjects.
Materials and Methods
Twelve healthy male subjects participated in this study.
Written informed consent was obtained from all participants.
Their mean age was 22.9 years (range 21–27 years). Each
had a normal medical history. The protocol was approved
by the Ethics Committee of Shinshu University School of
Medicine.
Study design
Study design is shown in Fig. 1. Once entering the study,
subjects were randomized through the distribution of sealed
envelopes assigning them to either the 100 mg group (n =6 )
or the 200 mg group (n = 6). The subjects in both groups
were administered with a glass of water (50 ml). Subjects
were given a bolus dose of midazolam 0.1 mg/kg intra-
venously for sedation. A single balloon enteroscopy (SBE)
(Olympus Co., Tokyo, Japan) was performed at 1 and 3 h
after administration of rebamipide. Each time, two biopsy
samples were gathered from the mucosa at the jejunum (at
about 100 cm anal site from the portion of Treitz’s ligament),
and two biopsy samples were obtained at the large curvature
of the antrum using conventional biopsy forceps. When
enteroscopy was performed, venous blood samples were
simultaneously taken from the subjects in both groups.
Measurement of obtained samples
After the jejunum and gastric mucus adhering to the
Fig. 1. Study design.T. Akamatsu et al.
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biopsy specimens was removed using filter paper,
rebamipide (attached to the surface well) of collected
jejunum and gastric specimens was washed away, and these
specimens were immediately placed in preserving tubes
and weighed. Biopsy specimens and serum were stored
frozen at −20 degrees until being assayed for COR. The
COR was determined by high-performance liquid chromato-
graphy as reported previously [22–23].
Safety assessment
All symptoms, the incidence of adverse events by exami-
nation of balloon endoscopy, and other complications
through this study period were observed carefully by endo-
scopists.
Results
COR in the jejunum
In the 100 mg group, the mean COR level was 146.3 ±
203.1 µM at 1 h after taking rebamipide, and 54.9 ± 47.8
µM at 3 h. In the 200 mg group, the mean COR level was
153.5 ± 183.1 µM at 1 h, and 36.0 ± 43.5 µM at 3 h. The
mean COR level in both groups was higher than 100 µM at
1 h, and higher than 1 µM at 3 h (shown in Fig. 2).
COR in the stomach
In the 100 mg group, the mean COR level was 68.3 ±
79.0 µM at 1 h after taking rebamipide, and 22.5 ± 19.2 µM
at 3 h. In the 200 mg group, the mean COR level was
173.9 ± 207.5 µM at 1 h, and 25.8 ± 28.0 µM at 3 h. The
mean COR level in both group was higher than 1 µM at 1
and 3 h (shown in Fig. 2).
COR in serum
In the 100 mg group, the mean COR level was
0.69 ± 0.220 µM at 1 h after taking rebamipide, and
0.87 ± 0.21 µM at 3 h. In the 200 mg group, the mean COR
level was 1.14 ± 0.51 µM at 1 h, and 1.33 ± 0.66 µM at 3 h.
The mean COR level was lower than 1 µM at 1 and 3 h in the
100 mg group, and lower than 10 µM in the 200 mg group
(shown in Fig. 2). The mean COR level was higher in the
200 mg group than in the 100 mg group.
Safety assessment
The incidence of adverse events and other complications
caused by the study drug and examination of endoscopy
were not observed throughout the study period.
Discussion
The mean COR levels in the jejunum were higher than
100 µM at 1 h and 1 µM at 3 h after taking rebamipide.
These results have shown the possibility of demonstrating
actions which rebamipide has, such as enhancing generation
of endogenous prostaglandins [16], inhibition of inflam-
matory cytokines [18], scavenging of oxygen free radicals
[19], preventing intestinal hyperpermeability, and stabilized
human intestinal barrier function [20]. On the other hand,
the COR which was administered by higher dosage of
rebamipide compared with indicating dosage for gastric
ulcer and gastritis were also measured in this study.
However, the mean COR levels in the jejunum were not
elevated despite administration of 200 mg of rebamipide.
Nakamura  et al. [ 24] investigated the localization of the
binding sites of rebamipide, 3H-rebamipide by binding
radioisotope, in rats with 100% acetic acid-induced gastric
Fig. 2. Gastric mucosa, small intestine and serum concentration of rebamipide at 1 h and 3 h after administration (mean ± SD, n =6
each). Broken lines show pharmacological actions of rebamipide have been confirmed by in vitro experimental studies to re-
quire COR of more than 1 µM to 100 µM.Local Tissue Concentration of Rebamipide
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injury. In the control rats, 3H-rebamipide was found to bind
to the surface epithelial cells. On the other hand, 3H-
rebamipide in the acetic acid-treated group was observed in
the lamina propria mucosa. Combination of autoradiography
and immune-histochemistry has revealed that iNOS-
immunoreactive cells had strong binding of 3H-rebamipide
in the acetic acid-treated group. This result may show
that rebamipide is induced to i-NOS-expressed sites, but
not to sites that do not to express i-NOS. In our study, we did
not use any stimulators to induce small intestinal injury,
such as NSAIDs. The result of our study showed COR in
the jejunum was not elevated despite using a higher dosage
of rebamipide. The COR for several organs of rats were
reported, localizing in the stomach and small intestine
mostly was shown compared with the other organs involving
serum levels [25]. The experimental data of this study was
limited as different given dosages were not examined. On
the other hand, the mean COR levels in the serum were
very low compared with the jejunum and the stomach, and
increased with the dosage (increased from 100 to 200 mg).
This result suggested that the COR presented in the jejunum
and the stomach resulted not from systemic circulation to
the GI lumen, but from topical.
There are several limitations to this study. First, the
effective concentration of rebamipide to various action
mechanisms is unknown in basic research and in humans. In
addition, the small intestine is an internal organ with wide
surface area compared with stomach. Therefore, there is the
necessity of investigating high-dose (more than 300 mg/day)
rebamipide dosing, in order to realize the preventive effect
of rebamipide with NSAID-induced small-intestinal injury.
It is necessary to investigate the COR in sufficient dosage
of rebamipide to demonstrate efficacy. Secondly, NSAID-
induced enteropathy is recognized not only in the jejunum
but also in the ileum. However, we could not obtain
specimens from the ileum. This was from an ethical perspec-
tive in using healthy subjects. In the future, new technology
such as a video capsule endoscopy (VCE) with a device for
obtaining biopsy specimens or with an elaborate sensor to
measure concentrations of drugs will make it possible to
study drug delivery in the entire small intestine.
Since developing VCE and balloon endoscopy, so-called
“obscure GI bleeding” is not obscure, and the incidence of
high frequencies ratio of small-intestinal complications,
related to NSAID use, is obvious. The preventive therapeutic
strategy for NSAID-induced complications is required not
only in the upper GI but in the small intestine and the lower
GI. However, there is no drug with efficacy for small
intestinal injury. Recently, Niwa et al. [26] reported the effi-
cacy of rebamipide in preventing NSAID-induced small-in-
testinal complications. They found small intestinal mucosal
injuries after taking diclofenac in 8 of 10 subjects in the
placebo group, but in only 2 of 10 in the rebamipide group
(p = 0.023). This result may suggest its being one candidate
drug for NSAID-induced small intestinal complications.
In conclusion, the COR in the jejunum has fitted in the
range which was sufficient to demonstrate protective actions
after taking an ordinary clinical dose and double dose,
however further study is required concerning COR in the
ileum.
Acknowledgment
The volunteers who participated in this study were
recruited by announcement on a public billboard for our
university students and hospital staff. The sponsors had no
other involvement in this study.
Disclosure
Dr. Akamatsu has received honoraria and consulting fees
from Astellas, Eisai, Otsuka, and Takeda. Dr. Akamatsu also
received research grants from Astellas, Eisai, Otsuka, and
Takeda within the last three years.
References
[1] Tympner, F.: Gastroscopic findings after therapy with
nonsteroidal anti-inflammatory drugs. J. Rheumatol.,  40,
179–181, 1981.
[2] Roth, S.H. and Bennett, R.E.: Non-steroidal anti-inflammatory
drug gastropathy. Recognition and response. Arch. Intern.
Med., 147, 2093–2100, 1987.
[3] Lakari, E.N., Smith, J.L., Lidsky, M.D., and Graham, D.Y.:
Gastroduodenal damage and dyspeptic symptoms in arthritis
patients during chronic nonsteroidal anti-inflammatory drug
use. Am. J. Gastroenterol., 82, 1153–1158, 1987.
[4] Bjarnason, I., Hayllar, J., Macpherson, A.J., and Russell,
A.S.: Side effects of nonsteroidal anti-inflammatory drugs on
the small and large intestine in humans. Gastroenterology,
104, 1832–1847, 1993.
[5] Bjarnason, I., Zanelli, G., Prouse, P., Smethurst, P., Smith, T.,
Levi, S., Gumpel, M.J., and Levi, A.J.: Blood and protein
loss via small-intestinal inflammation induced by non-
steroidal anti-inflammatory drugs. Lancet, 2, 711–714, 1987.
[6] Bjarnason, I., Price, A.B., Zanelli, G., Smethurst, P., Burke,
M., Gumpel, J.M., and Levi, A.J.: Clinico pathological
features of non steroidal anti inflammatory drug-induced
small intestinal strictures. Gastroenterology, 94, 1070–1074,
1988.
[7] Langman, M.J.S., Morgan, L., and Worrall, A.: Use of anti-
inflammatory drugs by patients admitted with small or large
bowel perforations and haemorrhage. Br. Med. J., 290, 347–
349, 1985.
[8] Bjarnason, I. and Takeuchi, K.: Intestinal permeability in
the pathogenesis of NSAID-induced enteropathy. J. Gastro-
enterol., 44 Suppl. 19, 23–29, 2009.
[9] Takeuchi, K., Tanaka, A., Ohno, R., and Yokota, A.: Role ofT. Akamatsu et al.
J. Clin. Biochem. Nutr.
260
COX inhibition in pathogenesis of NSAID-induced small
intestinal damage. J. Physiol. Pharmacol., 54 Suppl. 4, 165–
182, 2003.
[10] Graham, D.Y., Agrawal, N.M., Campbell, D.R., Haber,
M.M., Collis, C., Lukasik, N.L., and Huang, B.: Ulcer pre-
vention in long-term users of nonsteroidal anti-inflammatory
drugs: results of a double-blind, randomized, multicenter,
active- and placebo-controlled study of misoprostol vs
lansoplazole. Arch. Intern. Med., 162, 169–175, 2002.
[11] Silverstein, F.E., Graham, D.Y., Senior, J.R., Davies, H.W.,
Struthers, B.J., Bittman, R.M., and Geis, G.S.: Misoprostol
reduces serious gastrointestinal complications in patients with
rheumatoid arthritis receiving nonsteroidal anti-inflammatory
drugs. A randomized, double-blind, placebo-controlled trial.
Ann. Intern. Med., 123, 241–249, 1995.
[12] Park, S.H., Cho, C.S., Lee, O.Y., Jun, J.B., Lin, S.R., Zhou,
L.Y., Yuan, Y.Z., Li, Z.S., Hou, X.H., Zhao, H.C.,
Kachintorn, U., Kositchaiwat, C., and Lertkupinit, C.:
Comparison of prevention of NSAID-induced gastro-
intestinal complications by rebamipide and misoprostol: A
randomized, multicenter, controlled traial-STORM STUDY.
J. Clin. Biochem. Nutr., 40, 148–155, 2007.
[13] Yamamoto, T., Isono, A., Mishina, Y., Ebato, T., Shirai, T.,
Nakayama, S., Nagasawa, K., Abe, K., Hattori, K., Ishii, T.,
and Kuyama, Y.: Gastroduodenal mucosal injury in patients
taking low-dose aspirin and the role of gastric mucoprotec-
tive drugs: possible effect of rebamipide. J. Clin. Biochem.
Nutr., 47, 27–31, 2010.
[14] Ono, S., Kato, M., Imai, A., Yoshida, T., Hirota, J., Hata, T.,
Takagi, K., Kamada, G., Ono, Y., Nakagawa, M., Nakagawa,
S., Shimizu, Y., Takeda, H., and Asaka, M.: Preliminary trial
of rebamipide for prevention of low-dose aspirin-induced
gastric injury in healthy subjects: a randomized, double-blind,
placebo-controlled, cross-over study. J. Clin. Biochem. Nutr.,
45, 248–253, 2009.
[15] Ishihara, K., Komuro, Y., Nishiyama, N., Yamasaki, K., and
Hotta, K.: Effect of rebamipide on mucus secretion by
endogenous prostaglandin-independent mechanism in rat
gastric mucosa. Arzmein-Forsch/Drug Res., 2, 1462–1466,
1992.
[16] Yamasaki, K., Kanbe, T., Chijiwa, T., Ishiyama, H., and
Moria, S.: Gastric mucosal protection by OPC-12759, a
novel antiulcer compound in rats. Eur. J. Phrmacol., 142, 23–
30, 1987.
[17] Murakami, K., Okajima, K., Uchiba, M., Harada, N., Johno,
M., Okabe, H., and Takatsuki, K.: Rebamipide attenuates
indomethacin-induced gastric mucosal lesion formation by
inhibiting activation of leukocytes in rats. Dig. Dis. Sci., 42,
319–325, 1997.
[18] Aihara, M., Azuma, A., Takizawa, H., Tsuchimoto, D.,
Funakoshi, Y., Shindo, Y., Ohmoto, Y., Imagawa, K.,
Kikuchi, M., Mukaida, N., and Matsushima, K.: Molecular
analysis of suppression of interleukin-8 production by
rebamipide in Helicobacter pylori-stimulated gastric cancer
cell lines. Dig. Dis. Sci., 43, 174S–180S, 1998.
[19] Yoshikawa, T., Naito, Y., and Kondo, M.: Free radical
scavenging activity of the novel anti-ulcer agent rebamipide
studied by electron spin resonance. Arzneim-Forsch/Drug
Res., 3, 63–366, 1993.
[20] Banan, A., Fitzpatrick, L., Zhang, Y., and Keshavarzian, A.:
OPC-compounds prevent oxidant-induced carbonylation and
depolymerization of the F-actin cytoskeleton and intestinal
barrier hyperpermeability. Free Radic. Biol. Med., 30, 287–
298, 2001.
[21] Mizoguchi, H., Ogawa, Y., Kanatsu, K., Tanaka, A., Kato, S.,
and Takeuchi, K.: Protective effect of rebamipide on
indomethacin-induced intestinal damage in rats. J. Gastro-
enterol. Hepatol., 6, 1112–1119, 2001.
[22] Shioya, Y. and Shimizu, T.: High-performance liquid
chromatographic procedure for the determination of a new
anti-gastric ulcer agent, 2-(4-chlorobenzylamino)-3-[2(1H)-
quinolinon-4-yl] propionic acid, in human plasma and urine.
J. Chromatogr., 434, 283–287, 1988.
[23] Akamatsu, T., Nakamura, N., Furuya, N., Shimizu, T., Gotou,
A., Kiyosawa, K., Katsuyama, T., Osumi, T., Hirao, Y., and
Miyamoto, G.: Local gastric and serum concentrations of
rebamipide following oral ingestion in healthy volunteers.
Dig. Dis. Sci., 47, 1399–1404, 2002.
[24] Nakamura, M., Akiba, Y., Matsui, H., Tsuchimoto, K., and
Ishii, H.: Rebamipide binds to iNOS-positive cells in acetic
acid-treated but not in ethanol-treated rat gastric mucosa.
Aliment. Pharmacol. Ther., 18 Suppl. 1, 76–81, 2003.
[25] Shioya, Y.: Iyakuhin Kenkyu, 20, 522 (abstract in English),
1989.
[26] Niwa, Y., Nakamura, M., Ohmiya, N., Naeda, O., Ando, T.,
Itou, A., Hirooka, Y., and Goto, H.: Efficacy of rebamipide
for dicrofenac-induced small-intestinal mucosal injuries in
healthy subjects: a prospective, randomized, double-blinded,
placebo-controlled, cross-over study. J. Gastroenterol., 43,
270–276, 2008.